Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 13/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383813 | 0.82 | RORC (0.43) | KDM4EALDH1A1RORCSMN1; SMN2 | |
| SCHEMBL4384886 | 0.81 | PKM (0.38) | CCR6KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4395449 | 0.81 | CCR6 (0.49) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL4381060 | 0.81 | TP53 (0.37) | CCR6KDM4EALDH1A1RORCCYP2C19 | |
| SCHEMBL4385274 | 0.80 | PKM (0.41) | ALDH1A1RORCCYP2C19SMN1; SMN2 | |
| SCHEMBL4382701 | 0.79 | PKM (0.47) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4385346 | 0.77 | MEN1 (0.43) | RORCCYP2C19SMN1; SMN2 | |
| SCHEMBL4383060 | 0.77 | NAMPT (0.41) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4383772 | 0.75 | ATM (0.42) | ALDH1A1RORCSMN1; SMN2 | |
| SCHEMBL4395456 | 0.75 | TYMS (0.41) | KDM4EALDH1A1CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | CCR6 2413/4885CCNA2 2430/4885CDK2 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.